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Background: NICE guidance states that cognitive behavioural therapy (CBT) should be offered to all patients with
psychosis. However, there is a need to improve access to therapeutic interventions. We aim to train frontline
mental health staff to deliver brief, structured CBT-based therapies. We have developed and piloted a manualized
intervention to support people with psychosis and anxious avoidance or depression to work towards a personal
recovery goal.
Methods/Design: The ‘GOALS Study’ is a pilot randomized controlled trial comparing usual care plus an 8-week
intervention with usual care alone. The key objective is to assess clinical feasibility (recruitment and randomization;
compliance with the treatment manual; acceptability and satisfaction; progress towards goals). A secondary
objective is a preliminary evaluation of efficacy. Sixty-six participants with a diagnosis of psychosis, plus symptoms
of depression or anxiety will be recruited from adult mental health services. Those currently refusing medication, in
receipt of CBT, or with a primary diagnosis of an organic mental health problem or substance dependency will be
excluded. Following informed consent, randomization will be independent of the trial team, at a 50:50 ratio, at the
level of the individual and stratified by main problem focus. Following randomization, participants allocated to the
intervention group will begin the 8-week intervention with a local, trained member of staff, supervised by the study
coordinator. Outcomes will be assessed blind to treatment condition at 0, 12 and 18 weeks post-randomization. The
primary outcome measure for the efficacy analysis will be activity levels at 12 weeks. Secondary outcome measures
include mood, psychotic symptoms, quality of life and clinical distress. A health economic analysis comparing service
use in each condition will also be performed. Recruitment began in March, 2013 and is ongoing until December, 2014.
Discussion: This is the first trial of the GOALS intervention. The approach is brief and staff can be readily trained in its
delivery: there is therefore potential to develop a cost-effective intervention that could be widely disseminated. If the trial
proves clinically feasible and demonstrates preliminary evidence of efficacy, a large multi-site trial will be warranted.
Trial registration: Current Controlled Trials ISRCTN: 73188383. http://public.ukcrn.org.uk/search/StudyDetail.aspx?
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It is estimated that over half a million people in the
UK alone suffer from psychosis. For many, recovery is
impeded by high levels of distress, often resulting
from persisting psychotic symptoms, stigma and social
exclusion [1,2]. There is evidence for an increased
prevalence of anxiety and depression in people with
psychosis, in comparison with the general population
[3,4]. These difficulties can prevent people from engaging
in meaningful activity and from achieving valued goals.
Helping people to overcome these obstacles and achieve
their goals should promote recovery.
There is evidence that cognitive behavioural therapy
(CBT), in conjunction with antipsychotic medication, is
effective in reducing distressing symptoms and hospi-
talizations, in comparison with medication alone [5,6].
Consequently, the latest National Institute for Health
and Care Excellence (NICE) guidance [7] states that
CBT should be offered to all people with psychosis or
schizophrenia. New cognitive behavioural approaches
for psychosis have been developed to focus specifically
on recovery-oriented outcomes, such as increased activity
levels and hopefulness about the future [8]. However,
given the large number of patients with psychosis and the
limited availability of CBT-trained professionals, there is a
need to consider ways of improving access.
Brief, evidence-based CBT approaches are available, as
adopted in the UK ‘Improving Access to Psychological
Therapies’ programme; namely, graded exposure and
behavioural activation. These interventions are effective
in reducing anxiety and depression [9-11], and are often
applied in CBT for psychosis, to help with concurrent
difficulties with mood, and to help manage persisting
psychotic symptoms [12]. Importantly, the approaches can
be readily disseminated: ‘nonspecialist’ staff can be trained
to deliver behavioural activation effectively, following brief
training [13,14]. However, little evidence is available
regarding their efficacy in this group. Based on these
evidence-based methods, we have developed a new inter-
vention designed to help people meet valued, personal
goals and improve recovery, which can be delivered by
frontline mental health staff as part of the team’s package
of care.
Preliminary study
We have completed a small pre-pilot study to evaluate the
feasibility of the model of delivery, and the effectiveness of
the intervention [15]. Six staff members, including nurses
and occupational therapists, completed training over four
half-days, with ongoing group supervision from a clinical
psychologist. They delivered the intervention to 12 ser-
vice users, all of whom were outpatients attending
early-intervention or community mental health services.
All participants showed increased activity and clinicalimprovement, and were able to meet their goals. Both staff
and service users gave positive feedback on the interven-
tion. Participant and staff feedback was sought following
completion of the study [16], which informed a number of
changes to the treatment manual and training package.
Pilot randomized controlled trial
The aim of the study is to run a pilot randomized con-
trolled trial of this intervention, specifically designed for
people with psychosis: the GOALS study (‘Getting On top
of Anxiety and Low mood’). Following the same structure
as the pre-pilot study, therapy will be delivered over eight
weekly sessions by frontline mental health staff, after
receiving brief training (2 days) and fortnightly case
supervision from a clinical psychologist, to provide ongoing
support and to ensure fidelity to the treatment protocol.
Staff will come from a range of professional backgrounds,
including nursing, occupational therapy and psychology
(assistants) and are likely to have little or no previous ex-
perience in delivering CBT-based therapy. The manualized
intervention aims to improve recovery, social inclusion and
social functioning and reduce distress, and will be evaluated
in comparison to a treatment-as-usual (TAU) control
group, which will be standard community mental health
care. This will inform the further development of the
intervention and training and will provide information
for a larger multicentre trial.
The main objective of the study is to assess the clinical
feasibility of delivering the therapy package to patients
with a diagnosis of psychosis and concurrent anxiety or
depression. We will assess this on the basis of successful
recruitment and randomization, therapist and participant
compliance with the treatment manual and good levels
of acceptability and satisfaction with the treatment and
progress towards participants’ chosen goals. A secondary
objective is a preliminary evaluation of efficacy. For this,
the primary outcome is activity levels at post-intervention;
our assessment time point of interest. In addition we will
examine a range of secondary outcomes at both post-
intervention (12 weeks) and follow-up (18 weeks). These
include assessments of mood, psychotic symptoms, well-
being and clinical distress. A health economic analysis,
assessing service use, will also be performed, to assess the
cost effectiveness of the intervention.
Methods
Participants and study setting
The study aims to recruit 66 participants from community
psychosis teams (both early intervention and recovery)
within one UK National Health Service (NHS) trust for
mental health: the South London and Maudsley NHS
Foundation Trust, which provides treatment for 10,000
people with psychosis. Recruitment will initially be tar-
geted at six teams (with caseloads in excess of 150 service
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is estimated that at least 40% (n = 360) of these service
users will meet our criteria and that, at a very conservative
estimate, at least 120 of these would consent to participate
in a research trial, thus providing ample numbers.
Potential participants with a diagnosis of psychosis
and who are identified by their clinical team as having
problems in daily functioning owing to anxiety-related
avoidance or depression will be invited to learn more
about the study. The inclusion criteria are: diagnosis of a
schizophrenia spectrum disorder or currently experiencing
psychotic symptoms (for example, with diagnoses of per-
sonality disorder, bipolar disorder or psychotic depression);
18 to 65 years old (or accessing adult services); clinical
levels of anxiety-related avoidance or depression on out-
come measures; and a desire to increase the current level of
activities. Exclusion criteria are patients not meeting the
above criteria, or who are currently refusing all medication;
or who are currently or recently (previous 3 months) in
receipt of CBT; or who have a primary diagnosis of an
organic mental health problem; or who have a primary
substance dependency.
Ethical approval
The study has been reviewed and given a favourable
opinion by the London Chelsea National Research Ethics
Committee (reference: 12/LO/1523).
Interventions
Treatment-as-usual (TAU) control condition
Participants in the TAU group will continue to receive
all the treatment and support they received before the
start of the trial, including input from their general
practitioner and psychiatrist, and will be seen by their
care coordinator at least monthly. As we expect there
to be some variation in delivery and take-up of TAU, all
service contacts will be monitored for the trial duration.
Participants in the TAU arm will be offered the interven-
tion after the end of the trial (after four months). The
post-TAU treatment does not form part of this study and
no data will be collected on the participants in the TAU
arm after the end of the study.
Treatment as usual (TAU) + GOALS intervention
Participants allocated to the TAU +GOALS intervention
will continue to receive all the treatment and support
they received before the start of the trial, including input
from their general practitioner and psychiatrist, and will
be seen by their care coordinator at least monthly. Follow-
ing randomization, participants will receive eight weekly
CBT sessions with a trained member of staff, each for
around one hour (these may be slightly shorter or longer,
depending on client preference and where longer sessions
are needed to practice particular skills in the community),within a 12-week period. In addition, participants will re-
ceive a ‘booster’ session at one month after completion of
the final therapy session (this should be at approximately
14 weeks). As described earlier, the intervention is based
on two established, brief CBT interventions: graded ex-
posure for anxious avoidance and behavioural activation
for depression.
The therapy is targeted at supporting people to achieve
a personally desired, behavioural recovery goal (increasing
activity and social engagement), through targeting symp-
toms of depression or anxiety. The therapist’s manual
covers both anxiety (graded exposure) and depression
(behavioural activation) techniques, and these techniques
are structured very similarly. The techniques chosen will
depend on whether the client’s difficulties in completing a
particular recovery goal arise from avoidance of anxiety
(for example, particular fears or physical symptoms of
anxiety) or depression-related difficulties (for example,
lack of motivation or energy, interference of negative
thoughts or content of voices). The manual comprises
detailed session-by-session plans and client hand-outs,
for example educational materials on depression and
anxiety and an explanation of vicious and virtuous cy-
cles of reduced activity levels and avoidance; guidance
on setting specific, measurable attainable, relevant and
time-bound (SMART) goals with clients; advice on break-
ing down longer-term goals into more manageable steps;
setting up weekly in-session and homework tasks; and a
section on troubleshooting any difficulties encountered in
implementing the therapy. The sessions aim to teach ser-
vice users the skills to achieve their chosen goal and to
use those skills independently in the future to reach new
goals. The final weekly session includes meeting with a
trusted friend, carer or mental health professional (if
agreed with service users) to discuss the purpose of the
sessions, to reinforce achievements, and to think together
about ways in which that person might be able to continue
to support the client, where appropriate. Service users are
then invited to set a small new goal to complete together
with their support person, which is reviewed at the
booster session one month later.
Outcomes and timeline
The timeline is outlined in Figure 1. Following informed
consent from each participant, all outcomes will be
assessed by a study researcher. Assessment time points
are before randomization (‘baseline’ or 0 weeks), 12 weeks
after randomization (‘post-treatment’) and 18 weeks after
randomization (‘follow-up’). All outcomes will be assessed
in all participants at all time points, with the exception of
the Client Service Receipt Inventory (see next), which will
be assessed at 0 and 18 weeks only. Baseline assessments
will be completed within a time window of 4 weeks. Post-
randomization assessments will have to be completed
Potential participants identified by clinical teams and referred to study
Screening:
Eligibility screen completed 
either in person or on the 
telephone with study Assistant 
Psychologist.
0 weeks - Consent & Baseline Assessments:
Written consent and completion baseline 
assessment measures.
Randomization (n = 66)
Randomized to treatment as usual 
(n = 33)
Participant receives care co-
ordination as usual
Randomized to TAU + GOALS 
intervention (n = 33)
Participant receives 8 weekly 
sessions with trained member of 
staff.
18 Week Assessment
18 Week Assessment (follow up)
12 Week Assessment 
14 Weeks: Therapy Booster 
Session:
12 Week Assessment (post 
treatment)
Excluded
Not meeting inclusion 




Figure 1 Study flowchart.
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weeks after the planned assessment time point. All par-
ticipants (TAU and TAU+GOALS) will have a brief semi-
structured interview with a study assistant psychologist
following completion of their final 18 week assessments.
Individual goal attainment and service user consultant
conducted interviews will only be undertaken in the
TAU + GOALS intervention group. Fifteen participants
will undertake this additional semistructured interview
with a service user consultant. We will aim to purposely
sample participants with a range of responses to the
treatment, including those who have achieved their
goals and those who have not been able to do so, follow-
ing the intervention.Screening
Screening will involve assessment using the Hospital
Anxiety and Depression Scale [17], which includes clinical
‘cut-off ’ scores. To be eligible to enter the study, service
users must score above the clinical cut-offs (>8) on either
the depression or anxiety subscales.Primary outcome
The primary outcome measure for the study is activity
level, which is assessed using the Time Budget Measure
[18,19]. This is an individualized measure of activity over
an average week, which was specifically designed for use
with people with psychosis, and has been used in at least
one trial with this population [20]. It is sensitive to change
and has a high inter-rater and test-retest reliability [19].Secondary outcomes
Psychotic symptoms will be measured using two validated
and commonly used assessment measures: the Positive
and Negative Syndromes Scale [21], which is a semistruc-
tured interview, looking at the presence of symptoms over
the previous two weeks, and the Psychotic Symptom
Rating Scales [22], which measure the dimensions of de-
lusional and hallucinatory experience over the previous
week. Anxiety and depression will be measured using
the Hospital Anxiety and Depression Scale, as described
earlier, plus an additional measure of anxious avoidance
(the Mobility Inventory) [23], since this will be targeted
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work towards particular personal goals that anxiety
might currently prohibit. Well-being, quality of life and
general distress will all be assessed using validated as-
sessment measures with good psychometric properties
(the Warwick-Edinburgh Mental Well-being Scale [24],
the Manchester Short Assessment of Quality of Life [25]
and Clinical Outcomes in Routine Evaluation - 10
(CORE-10) [26]). Cost effectiveness of the intervention
is an important target, if it is to be delivered in the UK
NHS. The Client Service Receipt Inventory [27] is a
measure developed to calculate cost effectiveness. It
consists of eight items that record a client’s contact with
mental health professionals and related services, such as
day services, criminal justice services, or prescriptions
and benefits received, over the previous four-month
period. Qualitative feedback will also be collected through
semistructured interviews, aiming to examine participants’
experience of the interventions and other care, blocks and
enablers of delivery of the intervention, and contextual
factors that might be associated with variation on
outcomes.
For all participants in the intervention group, progress
towards individualized client goals will be assessed weekly
by the staff therapist completing the intervention, using
ten-point visual analogue scales [28]. The scales were de-
veloped and piloted as part of the previous study and were
found to be simple and easy to complete. Additionally, to
assess the quality of treatment delivery, audio recordings
of three therapy sessions (early, middle and later sessions)
for each participant will be rated by expert supervisors for
therapist empathy using the Therapist Empathy Scale [29]
and therapist fidelity to the protocol.
Sample size
To determine sample size, we carried out a ‘liberal’
power calculation for efficacy signal detection: In our
pre-pilot uncontrolled feasibility study, we achieved
clinically worthwhile reductions in the Time Budget of
0.83 effect size (Cohen’s d) between pre- and post-
therapy, which is in line with published effect sizes for
these interventions in meta-analyses in nonpsychotic
client populations (range from 1.6 to 0.6: [9,11]). We
therefore estimate a change in Time Budget total scores
from 52.3 to 61.8 (pooled standard deviation, 11.2) be-
tween baseline and post-treatment in the GOALS group
and no change over time in the TAU group, an effect size
of 0.8. A liberal two-sided t test at significance level 0.1
was used to assess power. A sample size of 56 (28 patients
per group) would have greater than 90% power to detect
this change. Recruiting to N = 66 in total will allow for
15% missing data or other loss to follow-up. Minimizing
such losses and achieving a modest increase in recruit-
ment by a further 12 participants would also have 90%power to demonstrate a statistically significant effect at
the conventional 5% significance level.
Randomization
Following informed consent and completion of baseline
assessments, individuals will be randomized to one of the
treatment arms by the study coordinator. This will be
conducted independently of the trial team by the King’s
Clinical Trials Unit, using an online randomization sys-
tem. Randomization will be carried out at a 50:50 ratio
and will be at the level of the individual and stratified by
main problem focus (anxiety; depression), using random
permuted blocks (varying in size from three to six).
Blinding
To minimize systematic bias, all study members (includ-
ing the statistician and assistant psychologists conducting
the assessments) will be blind to treatment allocation, with
the exception of the study coordinator who will be respon-
sible for the allocation of therapy and clinical supervision.
For any breaks in blindness, another assistant psychologist
will be allocated to complete the next set of outcome mea-
sures where possible. If this is not possible for any reason,
this will be recorded in the trial master file. Treatment-
group-specific information, such as measures describing
the trained staff therapists or aspects of the therapy, will be
stored in a separate database and will only be made avail-
able to those analyzing the data once the blinded analyses
have been completed.
Data monitoring
Data will be entered into an SPSS spreadsheet by the
study researchers. There will be three separate spreadsheets
for each assessment time point (0, 12 and 18 weeks). All
data will be double-checked monthly for accuracy, referring
back to the paper-based forms. The data will be locked
following the completion and checking of the last partici-
pant at the final time point. The three separate SPSS
spreadsheets for each assessment time point will be
merged, once all data have been entered and checked. The
randomization data and trial data will only be linked once
all trial data collection is complete and the database is
locked. All databases will be organized according to
unique participant ID number (assigned at the point of
randomization), which will ensure that the databases are
merged correctly.
Assessment of safety
Serious adverse events and reactions will be monitored
and recorded throughout the study period, from consent
to the final follow-up assessment meeting. Assistant psy-
chologists will assess any serious adverse events occur-
ring over the course of the study at 12 weeks and 18
weeks. In addition, the study coordinator will review
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regarding serious adverse events. Should any additional
information arise, this will be recorded. The local NHS
trust procedures for grading serious untoward inci-
dents will be used. All serious untoward incidents are
recorded as part of trust policy on clients’ electronic
notes. Serious untoward incidents graded A to C will be
classed as adverse events or reactions, which are defined
as any events that result in death, serious injury or
hospitalization. No serious adverse events are expected to
occur as a result of the intervention; however, this will be
monitored carefully and any events will be reported to




The outcomes of most interest are successful recruit-
ment, randomization, quality and fidelity of the delivery
of treatment and participant’s compliance with the proto-
col, including both treatment adherence and completion
of research assessments. Descriptive statistics will be used
to summarize these feasibility aspects and confidence in-
tervals will be constructed for respective performance
indices.
However, we will also carry out some efficacy com-
parisons of CBT + TAU versus TAU. These analyses
will adhere to the intention-to-treat principle, with
data from all participants entered into the analysis, in-
cluding from all those who drop out of therapy (that is,
those who do not attend at all or who cease therapy) or
who miss some therapy sessions. Every effort will be made
to follow up all participants in both arms for research as-
sessments, and the analysis will use, where appropriate,
statistical techniques for handling missing data. Linear
mixed modelling will be used to compare mean outcomes
between the treatment arms at each of the two post-
treatment time points. More specifically, the outcome
measured at the post-treatment time points will feature
as the dependent variable and stratifier (main problem
focus), pre-randomization outcome measure score, time,
treatment arm and time × arm interaction term as ex-
planatory variables. Correlation between the two repeated
measures per person will be taken into account by includ-
ing a subject varying random intercept. Therapist effects
will be modelled by a further random intercept term that
varies at the level of the therapist. A detailed statistical
analysis plan has been written by the trial statistician.
If noncompliance with the active treatment (GOALS)
is high, a complier average causal effect analysis will be
considered, to estimate efficacy [30]. This might be
warranted, since an intention-to-treat analysis estimates
the effect of randomization group; that is, the treatment’s
effectiveness only equals the treatment’s efficacy if everyparticipant also receives the treatment that is allocated to
them. Conventional per-protocol or as-treated analyses
have long tried to address this but are subject to selection
bias.
Health economic analysis
Service use is to be measured with the Client Service
Receipt Inventory. Costs will be calculated by combining
service use data with available unit cost information. The
following comparisons between the groups at 12- and
18-weeks will be assessed: (i) proportion of patients
using each service included in the Client Service Receipt
Inventory; (ii) mean number of contacts with each ser-
vice for those with at least one contact; (iii) mean cost
of each service (including those with no contacts); (iv)
mean total cost.
The first three comparisons will be descriptive with no
tests of significance. The main focus will be on the com-
parison of total costs and for this we will use a regression
model with total cost as the dependent variable, the group
identifier variable as an independent variable, and baseline
costs as an additional independent variable. We will visu-
ally check the distribution of the regression residuals; if
these do not approximate a normal distribution, we will
use bootstrapping methods with 1,000 repetitions to gen-
erate 95% confidence intervals.
A cost-consequences analysis will be conducted by
viewing costs alongside efficacy measures. Cost effective-
ness will be assessed by combining costs with the primary
outcome of activity levels, using cost effectiveness planes,
which will indicate the probability that the intervention is
(i) cost saving with better outcomes, (ii) cost saving with
worse outcomes, (iii) cost increasing with worse outcomes
or (iv) cost increasing with better outcomes. These will be
constructed by saving the 1,000 bootstrapped regression
coefficients representing cost differences described previ-
ously and 1,000 bootstrapped regression coefficients repre-
senting outcome differences (change in activity levels) and
plotting these against each other as a scatterplot.
Qualitative analysis
All interviews will be audiotaped, transcribed and ana-
lyzed qualitatively using thematic analysis [31], and
indexed using NVivo software. Interviews conducted
by study assistant psychologists and service user con-
sultants will be analyzed separately, but outcomes will
be compared. Thematic analysis has a number of key
steps, including generating initial data-driven codes,
searching and refining key themes, and defining and
naming these themes before summarizing and producing
a final report. To check reliability, at least 15% of the
transcriptions will be second-coded and checked for
agreement, to ensure that the coding framework is
deemed reliable (at least 80% agreement).
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Anxiety and depression are commonly present in people
with psychosis and lead to inactivity and difficulties in
achieving personal goals. Cognitive behavioural therapy
for psychosis, which can be effective for emotional prob-
lems in psychosis [5,6,32], is a formulation-based therapy,
delivered by highly trained therapists over 16 to 20 ses-
sions, and, although recommended by NICE, is not widely
available [33]. There are, however, effective brief protocol-
based interventions, graded exposure and behavioural ac-
tivation, which use cognitive behavioural principles and
methods, for these problems. We have adapted these to
address the specific needs and problems of people with
psychosis, while ensuring a focus on personal recovery
goals, and achieved promising results in our pre-pilot
study [15]. The advantages of the GOALS approach are
that it is brief and that the frontline mental health workers
who are in regular contact with people with psychosis in
care settings can be readily trained in its delivery. There is
therefore scope for developing an effective intervention,
which can be made widely available at low cost, improving
access to psychological therapies for this client group. This
is the first trial of the GOALS intervention. The study also
aims to finalise the training curriculum and the treatment
manual, which we intend to publish and make available in
electronic form in the future. The trial is funded until
August 2015 and the results will be available in 2016. If
this intervention proves clinically feasible and demon-
strates preliminary evidence of efficacy, a large multi-site
trial will be warranted.
Trial status
Participants began to enter the trial in April 2013. Recruit-
ment will continue until December 2014.
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